Treatment of peritoneal carcinomatosis with intent to cure

J Surg Oncol. 2000 May;74(1):41-4. doi: 10.1002/1096-9098(200005)74:1<41::aid-jso10>;2-r.


Background and objectives: Low-grade malignant tumors arise in the abdomen, do not infiltrate, and "redistribute" on the peritoneum with no extraregional spreading. In these cases, aggressive surgery combined with localized chemotherapy may provide cure.

Methods: After removing the tumor with the regional peritoneum en bloc, intraabdominal hyperthermic chemoperfusion was performed throughout the abdominopelvic cavity. Alternatively, early intraabdominal chemotherapy, starting on the first postoperative day, was administered for 5 days.

Results: Forty patients affected with extensive peritoneal carcinomatosis underwent peritonectomy, with no residual macroscopic disease except in four cases. Seventy-five percent of the patients underwent locoregional chemotherapy. Major complications were observed in 40% of the patients and led to death in five; there was a direct correlation to the duration of surgery (P = 0.03). At a mean follow-up of 20 months, the overall 2-year survival was 61.4%, with a median survival of 30 months.

Conclusions: After a learning curve of 18 months, the feasibility of the integrated treatment increased to greater than 90%, and mortality dramatically decreased. The combined treatment resulted in a high survival rate in patients with extensive carcinomatosis who were no longer responsive to traditional therapies.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma / drug therapy
  • Carcinoma / mortality
  • Carcinoma / surgery*
  • Cisplatin / administration & dosage
  • Colorectal Neoplasms / pathology
  • Combined Modality Therapy
  • Female
  • Humans
  • Hyperthermia, Induced
  • Male
  • Middle Aged
  • Mitomycin / administration & dosage
  • Ovarian Neoplasms / pathology
  • Perfusion
  • Peritoneal Neoplasms / drug therapy
  • Peritoneal Neoplasms / mortality
  • Peritoneal Neoplasms / surgery*
  • Peritoneum / surgery*
  • Postoperative Complications
  • Survival Rate


  • Mitomycin
  • Cisplatin